granisetron


Also found in: Wikipedia.

granisetron

 [gră-nis´ĕ-tron]
an antiemetic used in conjunction with cancer chemotherapy or radiotherapy; administered orally or intravenously as the hydrochloride salt.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.

granisetron

Kytril® Oncology A 5-HT3–serotonin receptor antagonist antiemetic used for Pts receiving chemotherapy–eg, cisplatin, cyclophosphamide Adverse effects Headache–35%, constipation–30%, asthenia, somnolence, diarrhea
McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.

Granisetron

A serotonin antagonist drug that blocks the nausea receptors in the small intestine and is used to control sickness and vomiting after surgery and in patients on anticancer chemotherapy. It can be used in children. A brand name is Kytril.
Collins Dictionary of Medicine © Robert M. Youngson 2004, 2005
References in periodicals archive ?
[10] In a study conducted by Bhatacharjee DP et al, [21] palonosetron was proved to be an effective antiemetic than granisetron for prevention of postoperative nausea and vomiting.
Biotechnology company Heron Therapeutics (NasdaqCM:HRTX) announced on Friday that its New Drug Application (NDA) resubmission for SUSTOL (granisetron) Injection, extended release has been accepted for review.
All patients received antiemetic prophylaxis with dexamethasone, granisetron and/or droperidol using monotherapy in nine patients (22%), dual therapy in 30 patients (73%) and three agents in two patients (5%).
Following the re submission of SUSTOL (granisetron) Injection extended release, the company expects expects confirmation of acceptance from the US FDA, a Prescription Drug User Fee Act (PDUFA) goal date within the next few weeks as well as a six-month review by the US FDA.
Granisetron reduces postoperative nausea and vomiting throughout menstrual cycle.
Granisetron hydrochloride Bedford Laboratories 1/20/2006
[3,4] Granisetron was introduced in 1993 and was initially used only for prevention of chemotherapy-induced nausea and vomiting.
Net proceeds may be used by the company primarily for general corporate purposes, the commercial launch of SUSTOL (granisetron injection, extended release), funding its ongoing and future clinical trials, preclinical development work, other product development activities as well as general and administrative expenses.
Serotonin type 3 (5-[HT.sub.3]) receptor antagonists, such as ondansetron, granisetron and tropisetron, have been shown to reduce the incidence of PONV in children (4,6,7,12,13).